Angry Birds maker Rovio will float shares on the Nasdaq Helsinki stock exchange, confirming rumours of an imminent initial public offering (IPO) which emerged last month.
The developer of the first mobile game to hit one billion downloads will issue €30m in shares in the Finnish capital, where it is headquartered, it said in a statement.
McDonald’s faces its first strike since it opened in the UK in 1974, as well as protests by unions and the public at several restaurants over pay and working conditions.
Staff in Cambridge and Crayford, south-east London, walked out in a row over the use of zero-hours contracts and "inexplicably" low pay.
The Bakers, Food and Allied Workers Union (BFAWU) said the strike was being well supported. Members of other trade unions joined early-morning picket lines outside the two restaurants, while Labour leader Jeremy Corbyn offered his backing.
Novartis announced that its Chief Executive Officer Joseph Jimenez has informed the board of directors of his desire to step down in 2018. The company’s board has appointed Vasant Narasimhan, its Global Head of Drug Development and Chief Medical Officer, to the position of CEO, effective February 1, 2018. Narasimhan is a member of the Executive Committee.
UBS is mulling over shifting its trading headquarters from London to Frankfurt inside the European Union (EU), post Brexit, as Bloomberg report.
The Swiss firm’s investment bank employs about 4,800 bankers globally and could move 250 or more jobs out of London to Frankfurt and other European locations, two of the people briefed on the deliberations said, asking not to be identified as the talks are private.
The Trump administration on Thursday announced it has chosen four companies to build concrete prototypes of the president’s much-touted border wall.
Construction of the prototypes, to take place in San Diego, is the first step in fulfilling Trump’s campaign promise of building a "big, beautiful" wall stretching along the 2,000-mile Mexico border.
Swiss banks’ overall operating income fell last year for the fist time since 2012, Switzerland’s banking lobby said on Thursday, as the Alpine nation’s lenders grapple with negative interest rates and rising regulatory costs.
Switzerland’s banks, already hit by a clamp-down on tax evasion which has dampened the country’s position as a tax haven, saw aggregate operating net income fall 3.2 percent in 2016 to 62.5 billion Swiss francs ($65.1 billion).
"2016 was once again a difficult year for the banks in Switzerland," the Swiss Bankers Association (SBA) said while publishing its annual banking study.
Switzerland should be reintegrated into the Erasmus+ student exchange programme from the beginning of 2018, and not in 2021 as the government wants, says the Swiss Student Union.
On Monday a petition signed by 10,000 people was lodged with the federal government, demanding that Switzerland resume its negotiations with the EU on the subject so that Swiss students can be reintegrated in the programme by 2018 and to allocate sufficient financial resources to the scheme.
Gilead Sciences Inc agreed to buy Kite Pharma Inc in a $11.9 billion deal on Monday, as it looks to fuel growth with an emerging class of cancer immunotherapies that are expected to generate billions.
Gilead will pay $180 per share in an all-cash deal, representing a 29.4 percent premium over Kite’s Friday close. Kite’s shares were trading up at $178.15 before the bell.
For qualified investors / professional clients only
In order to proceed, you must confirm that you are a qualified investor based in Switzerland
The information contained in this section have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document.
Before investing in a product please read the latest prospectus carefully and thoroughly and note that funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. Commissions and costs have a negative impact on performance. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. The details and opinions contained in this document are provided without any guarantee or warranty and are for the recipient's personal use and information purposes only